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Abstract
The mass drug administration (MDA) program has been demonstrated its effectiveness in many filariasis-endemic regions. However, Kuningan as a filaria-
sis-endemic area had the MDA program coverage lower than the government targeted. One of a district in Kuningan, Cilimus District was a filariasis-endemic
area with the MDA program coverage in 2017 lower than government targeted (higher than 86%). The purpose of this study was to analyze the determinant
factors of compliance with the MDA program. The study was an analytical study with a cross-sectional design and was conducted from May to June 2018.
The sample of 106 people was taken from the population living in Cilimus District, Kuningan Regency, using a simple random sampling technique. The inde-
pendent variables were collected by a constructed questionnaire included age, education level, knowledge, attitude, health promotion, and family support. A
questionnaire also measured compliance with MDA as a dependent variable. Data analysis consisted of univariate, bivariate (chi-square and Fisher exact
test), and multivariate analyses (multiple logistic regression). The results showed that the variables of knowledge, attitude, MDA health promotion, and family
support influence compliance with the MDA (p-value < 0.05). Low knowledge and unawareness of the MDA health promotion proved to be the dominant
factors in non-compliance with the MDA program.
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Introduction
Lymphatic filariasis (LF) is one of the oldest and most
debilitating neglected tropical diseases that continue to
be a significant cause of morbidity in many parts of the
world. In 2002, it was estimated that LF is responsible
for the loss of 4.4 million Disability Adjusted Life Years
(DALYs) in men and over 1.3 million DALYs in
women.1 In 2000, the World Health Organization
(WHO) launched the Global Programme to Eliminate
Lymphatic Filariasis (GPELF), aiming to eliminate LF as
a public health problem by 2020. The GPELF includes
two strategies, 1) to interrupt LF transmission by con-
ducting mass drug administration (MDA) in all disease-
endemic regions; and 2) morbidity management and dis-
ability prevention for infected people.2 Mass drug admin-
istration  aims to treat entire populations at risk of the
disease with a combination of albendazole plus iver-
mectin or albendazole plus diethylcarbamazine adminis-
tered as a single dose once a year for at least five years.
Mass drug administration has been demonstrating its
effectiveness in many filariasis-endemic regions.
Thailand, as an endemic area for LF, over the years 2002
to 2011, conducted extensive MDA with high coverage
rates. It delineated LF transmission areas at the sub-vil-
lage level through periodic and regular monitoring sur-
veys. It demonstrated through its evaluation surveys–the
Stop-MDA surveys and Transmission Assessment
Surveys (TAS)–below transmission threshold rates that
enabled its validation of LF elimination.3
A recent study in India proved that participation in
MDA programs was a behavioral factor that can affect
the occurrence of filariasis (OR = 1.8 and OR = 13.75).4
In Indonesia, after the fifth year of the MDA program in
Pekalongan City, the area is no longer included in the fi-
lariasis-endemic areas and the transmission parameters
have no potential in causing the spread of filariasis.
Because the microfilaria rate was 0.32% with an average
microfilariae density of 167/mL blood; the antigen preva-
lence of the calculation was 0%; the infection rate was
0.06%; and the infective rate was 0%.5 Therefore, peo-
ple’s awareness and their willingness to participate in the
MDA program is the key factor in preventing the filaria-
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sis transmission.
West Java is one of the provinces that has become an
endemic area of LF in Indonesia. Nationally, West Java
has the fourth-highest number of filariasis cases in 2017,
with a total case of 907. These cases were distributed in
11 endemic districts/cities in West Java with a microfi-
laria rate of more than 1%.6 Meanwhile, in 2018, West
Java was in the third position as a province with the high-
est number of chronic cases of filariasis after Papua and
East Nusa Tenggara.7
One of the regencies in West Java which is a filariasis
endemic area is Kuningan Regency. In 2017, there were
30 chronic cases of filariasis that were distributed in 15
districts in Kuningan Regency. Since 2015, Kuningan has
participated in MDA programs. The coverage of MDA
program in 2017 showed that percentage of people who
take a drug from the total population was 78.61%, while
the percentage of people who take a drug from the total
target was 89%. This result showed that the percentage
of people who take a drug from the total population in
Kuningan was still below the government's target > 86%.
Cilimus District became an endemic filariasis area in
Kuningan, with two cases of filariasis found there.
Meanwhile, the percentage of communities in Cilimus
taking drugs from the total population was 72.39% (be-
low government target). Cilimus District is the second-
highest number of filariasis cases in Kuningan Regency.
There were four cases in 2017.
The success in national programs aimed at eliminating
Lymphatic Filariasis (LF) could be determined by many
factors. Community participation has been found to be
one of the major challenges to the success of the MDA
program. A lack of community participation hampers
program implementation of all drug administration pro-
grams rather than only MDA for LF.8
A recent study demonstrated that demographic fac-
tors (age, sex, income level, and area of residence) were
often associated with individual's compliance. The cause
of non-compliance was mostly due to fear of side ef-
fects,9-11 lack of awareness of the benefits of MDA, non-
attendance of health staff in the villages,11 and the indi-
vidual has not received MDA education.10 The purpose
of this study is to analyze the determinant factors (edu-
cation level, knowledge, attitude, socialization, fami ly
support) of compliance to MDA for LF in Cilimus
District, Kuningan Regency, Indonesia.
Method
This study was an analytic observational using cross
sectional design conducted from May to June 2018.
Population in this research was all citizens living in
Cilimus District, Kuningan Regency. The total popula-
tion was 15,066 households in Cilimus District. The sam-
pling was done using a simple random sampling tech-
nique. Initially, 106 subjects who met the study’s inclu-
sion criteria and approved informed consent were invited
to participate in this study. Each sample comes from
every different household. The inclusion criteria were as
follows: 1) the subject does not suffer from filariasis, 2)
the subject is aged 2 to 70 years, 3) he or she does not
suffer from severe illness, 4) the woman is not pregnant
and should not get pregnant during the MDA program,
and 5) he or she is willing to become a sample in this
study. The collection of the data was done by face-to-face
interviews using a constructed questionnaire. The
enume rators were the public health workers who had
been previously trained to conduct data collection in the
community.
Independent variables and dependent variables were
the primary data. Independent variables consisted of age,
education level, knowledge, attitude, MDA health pro-
motion, and family support. This study measured knowl-
edge about filariasis and the benefits of the MDA pro-
gram in preventing the spread of filariasis. The family
support variable indicates whether there was support for
taking filariasis drugs from family members who live in
one house. Families being close to one another are always
ready to provide information, rewards, instrumental and
emotional support. Family support in the study comes in
different forms: encouragement, informing family mem-
bers about the benefits and risks of medication non-ad-
herence, and reminding family members when the res -
pondents forget to take medication.
The level of education was divided into two cate-
gories: In the low education category are included res -
pondents who are either illiterate or graduated from ele-
mentary school and junior high school; in the high edu-
cation category are included respondents who graduated
from high school and college. Knowledge and attitude
variables were obtained from the score when they an-
swered questions in the questionnaire. The score of
knowledge and attitude was then compared with the me-
dian value because they were not normally distributed. If
the score was less than the median value, the respondent
has low knowledge and a negative attitude. Conversely,
if the score of knowledge and attitude was higher or
equal to the median value, the respondent has a high level
of knowledge and positive attitude. The MDA health pro-
motion, as an independent variable, was divided into res -
pondents who have received MDA health promotion and
the respondents who were not informed of the health
promotion. Family support was grouped into two cate-
gories–the respondents who were encouraged by their
family members to take filariasis drugs and the respon-
dents who were not assisted by their family. The compli-
ance to MDA for LF as a dependent variable was also
measured by a constructed questionnaire. The definition
of compliance to MDA in this study was adherence to fi-
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lariasis preventive medication until the end of treatment
following the Regulation of the Minister of Health of the
Republic of Indonesia Number 94 of 2014 concerning fi-
lariasis control.
Before conducting data analysis, data management
processes are first carried out consisting of editing, cod-
ing, processing, and cleaning. The data including univari-
ate, bivariate, and multivariate were analyzed using the
chi-square, Fisher exact test, and multiple logistic regres-
sion. The Ethics Committee has approved this study from
Kuningan Health Science Institute/Sekolah Tinggi Ilmu
Kesehatan Kuningan (No. 012/EP/STIKKU/2018).
Results
The univariate analysis results (Table 1) showed that,
of 106 res pondents, most of them received low education
(59.4%). For knowledge, respondents with low and high
knowledge had almost the same proportion (50.9% and
49.1% respectively). Similarly, the proportion of respon-
dents who had negative and positive attitudes was equal,
at 50% of each. The majority of respondents received
support from their families to take filariasis drugs
(65.1%). Most of the respondents received socialization
about filariasis from health workers (70.8%). Most res -
pondents (94.3%) received filariasis drugs. For the de-
pendent variable, majority of the respondents took the
preventive drug in the MDA program in 2017.
Bivariate analysis shown in Table 2 indicated that the
variables of knowledge (OR = 25; 95% CI = 3.255–
199.75), attitude (OR = 4.8; 95% CI = 1.484–15.76),
family support (OR = 3.23, 95% CI = 1.163–8.945), and
MDA health promotion (OR = 11.53; 95% CI = 3.64–
36.428) had significant relationship with compliance to
the MDA program. With regard to the variables of age
and level of education, there was no significant relation-
ship with compliance to MDA (p-value > 0.05).
After bivariate analysis, five variables can enter into
the multivariate model (p-value ≤ 0.25). These variables
include age, level of knowledge, attitude, family support,
and the MDA health promotion. From the multivariate
analysis process with multiple logistic regression, the re-
sults of the final multivariate model were obtained as
shown in Table 3.
The final model of multivariate analysis by multiple
logistic regression demonstrated that the level of knowl-
edge (p-value = 0.015) and MDA health promotion (p-
value = 0.004) had p-value ≤ 0.05. Therefore, the level
of knowledge (OR = 13.68; 95% CI = 1.648–113.565)
and MDA health promotion from health workers (OR =
5.95, 95% CI = 1.754–20.196) were the dominant vari-
ables affecting compliance to MDA program (p-value ≤
0.05).
Table 1. Characteristic of Respondent and Compliance with the Mass Drug   
              Administration Program
Variable                                    Category                               n                  %       
                                                                                                                     
Age                                            > 43 years                           46              43.4
                                                 ≤ 43 years                           60              56.6
Level of education                     Low                                     63              59.4
                                                 High                                    43              40.6
Level of knowledge                   Low                                     54              50.9
                                                 High                                    52              49.1
Attitude                                     Negative                              53              50.0
                                                 Positive                                53              50.0
Family support                          No                                       37              34.9
                                                 Yes                                      69              65.1
MDA health promotion            No                                       31              29.2
                                                 Yes                                      75              70.8
Compliance to MDA                 Do not take drugs               19              17.9
                                                 Take drugs                          87              88.1
Note: MDA = Mass Drug Administration
Table 2. Relation of Respondent Characteristic and Compliance with the Mass Drug Administration Program for Lymphatic 
              Filariasis in Kuningan Regency
                                                                                            Compliance with MDA
                                                                                                                                                                                          
Variable                             Category             Did not Take Drugs       Took Drugs             Total               p-value          OR (95% CI)
                                                                            n             %                n         %             n          %
Age                                     > 43 years old           12          26.1             34       73.9          46        100            0.055                         2.672
                                     ≤ 43 years old            7          11.7             53       88.3          60        100                                (0.957–7.461)
Level of education              Low                          13          20.6             50       79.4          63        100            0.379                         1.603
                                          High                           6          14.0             37       86.0          43        100                                (0.557–4.612)
Level of knowledge             Low                          18          33.3             36       66.7          54        100          0.0001                         25.00
                                          High                           1            1.9             51       98.1          52        100                            (3.255–199.747)
Attitude                              Negative                   15          28.3             38       71.7          53        100            0.004                         4.836
                                          Positive                       4            7.5             49       92.5          53        100                              (1.484–15.760)
Family support                    No                            11          29.7             26       70.3          37        100            0.016                         3.226
                                          Yes                             8          11.6             61       88.4          69        100                                (1.163–8.945)
MDA health promotion      No                           14          45.2             17       54.8          31        100          0.0001                       11.529
                                          Yes                             5            6.7             70       93.3          75        100                                (3.64–36.428)
Notes: MDA = Mass Drug Administration; OR = Odds Ratio; CI = Confidence Interval
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Discussion
An information bias might occur in this study when
asking about attitude variables. During the study, the res -
pondents were sometimes hesitate to answer the ques-
tions, because of a fear for a bad score if the answers giv-
en were not appropriated. So, there was a possibility that
the answers given by the respondents were not sincere.
Therefore, authors explained repeatedly to res pondents
to answer truthfully and answer according to what was
experienced by respondents and not compete to get the
highest score. This information bias can be a weakness in
this study. The strength of this study was the examination
of the effect of predisposing/enabling (age, education le -
vel, knowledge, and attitude), reinforcing (family sup-
port), and enabling (MDA health promotion) factors that
influence people's behavior to adhere to the MDA pro-
gram.
This study proved that knowledge of MDA plays a
key role in determinating compliance with the MDA pro-
gram, which was also demonstrated in previous stud-
ies.10,11 Adhikari, in his study at an endemic district of
Nepal, concluded that respondents who understood the
side effects during an MDA campaign had a lower preva-
lence of non-compliance compared to those who have
not understood (9.4% vs. 33.2%, p-value < 0.001).12
Likewise, a study in Burdwan District of West Bengal,
India, showed that the lack of community awareness re-
garding MDA activity is also an influencing factor of
compliance to the MDA program with 16.88% of the
res pondents unaware of the MDA.13 Hussain within the
study in India revealed that the cause of non-compliance
is lack of awareness of the benefits of MDA.11
According to the theory of Lawrence Green, health
behavior can be influenced by three main factors, which
are (1) predisposing factors manifested by knowledge,
attitudes, beliefs, values, and so on; (2) enabling factors
manifested by the physical environment, availability of
health facilities such as health services, medicines, la-
trines, and so on; and (3) reinforcing factors manifested
by the attitudes and behavior of health workers or other
officers, which are reference groups of community be-
havior. Knowledge was included in the predisposing fac-
tor as it can determine compliance with the MDA pro-
gram. Knowledge can be influenced not only by the re-
spondent's formal education level but also by accessing
information on the MDA program. The information
could either be obtained on social media (Facebook,
Instagram, Twitter, etc.), print media (newspapers, ma -
ga zines), electronic media (television, internet, radio,
etc.), or more importantly by healthcare workers.10
Despite having low education level, the respondents in-
creased their knowledge by seeking information about fi-
lariasis through various media sources or at least having
heard information about filariasis. This knowledge, ulti-
mately, is the most significant factor that affects the de-
cision of participants.
Apart from knowledge, attitude toward MDA is also
a major factor that will determine respondents' behavior.
In this study, half of the respondents demonstrated a po -
sitive attitude, and half showed a negative attitude. This
study also indicated that the respondents’ attitudes had a
significant relationship with compliance to the MDA pro-
gram, consistent with previous studies. The study in India
found out that the subjects who did not consume the
medication feared experiencing side effects and they
“don’t have faith in a tablet”.14 Perceived vulnerability,
perceived severity, perceived benefits, and perceived bar-
riers were determinants of adherence to the MDA pro-
gram based on a study conducted by Widjanarko, et al.15
In general, the majority of respondents had a good per-
ception and most of them felt the need to take preventive
medicine for filariasis.15
Several MDAs in various countries have encountered
the mistrust of the communities in the MDA program.
These include suspicions that the drugs are being used to
poison children, being used as birth control, and even
cause erectile dysfunction.8 Another reason for non-com-
pliance was not receiving the drug, not being ill, or feel-
ing healthy. Cabral, et al.,10 stated that some previous
studies showed about two-thirds of infected people re-
main asymptomatic; thus, they did not see the benefits of
treatment. Also, individuals do not see any morbidity
caused by filariasis in their immediate surroundings. For
this reason, they did not follow the instruction they re-
ceived.10
Furthermore, the most popular reason for drug non-
compliance in the MDA program is the fear of side ef-
fects, which was reported in prior studies.8,11,16,17 In the
Pabean area, Indonesia, the respondents, most of whom
were batik factory workers, were afraid of suffering from
dizziness, nausea, and muscle pain after taking the drugs,
which may prevent them to continue their work at the
factory later.16 The percentage of people who experi-
enced side effects was tiny which should not be the
biggest concern. Therefore, the information on side ef-
fects should be well explained in any educational pro-
gram to help the people understand and overcome their
unnecessary fear of side effects; and recognize the impor-
tance of taking the drugs to protect not only themselves
but also their family members.
Table 3. Final Model of Multivariate Analysis by Multiple Logistic Regression
Variable                                      p-value          Exp (B)             95% CI              
                                                                                                               
Level of knowledge                      0.015           13.679        1.648–113.565
MDA health promotion                0.004             5.952          1.754–20.196
Notes: MDA = Mass Drug Administration; CI = Confidence Interval
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The study conducted by Ojha, et al.,18 showed that
the national LF program in Nepal provided additional
health education to drug distributors about drug dosage.
So they obtained clear information about potential drug
side effects and what they should do if they find a drug
side effect case in the population. Comprehensible infor-
mation on drug side effects was also shared with the com-
munity in Nepal. People were advised to go to the nearest
health facility immediately if they experienced nausea,
fever, headache, dizziness, or other symptoms after tak-
ing the drug.
The present study found that family support was also
one of the factors associated with compliance to MDA.
Family support in the study included encouragement, in-
forming family members about the benefits and risks of
not taking the medication as instructed, and reminding
family members when the respondents forget to take
medication. Families are generally close to one another
and have a great influence on each other’s decisions.
They can effectively share their knowledge about MDA
and always support or remind respondents to take drugs
to prevent filariasis. Hence, to improve MDA compliance
in general, it is important to educate other family mem-
bers to raise their LF awareness.
The MDA health promotion is a wide range of health
services, which the main goal is to raise public knowledge
about filariasis, together with other actions to contain fi-
lariasis. In this study, the MDA health promotion was a
determinant factor in compliance to the MDA program,
similar to previous studies. In the study of Adhikari, et
al.,12 the respondents who were visited by health workers
in their homes during the MDA campaign (75.9% vs
24.1% p-value < 0.001, ORadj = 4.85 (95% CI = 2.448–
9.594) had signi ficantly higher compliance than those
who did not. A study conducted by Marathe in India,19
showed 255 persons did not consume the drug among
them 11.67% of the households had prior information
regarding MDA. Information, education, and communi-
cation (audiovisual aids) activity reached only 31.67%
of households.
Hussain, et al.,11 illustrated in his study that the in -
adequate training of drug distributors, poor health com-
munication activities before the MDA campaign com-
menced, and the absence of follow-up by health workers
following MDA were a few of the operational difficulties
encountered during the MDA campaign. Although the
MDA health promotion benefits MDA compliance
among respondents, it should be well planned and fol-
lowed up by health workers.11 For successful implemen-
tation of MDA programs, good planning, educational
campaigns promoting the benefits of MDA, adoption of
measures to minimize the impact of adverse effects, and
improvement of drug distribution logistics are need-
ed.10,20,21
Additionally, regular and continual health informa-
tion about MDA should be conducted through interper-
sonal communication by frontline health workers and
mass media communication.22 Likewise, retraining of
service providers before MDA activities may help im-
prove the MDA program's outcomes.11,22 The results of
a study conducted by Silumbwe in Africa,23 found out
that the main factors facilitating the implementation of
MDA for filariasis programs were awareness creation
through innovative health education programs in the
community, creation of partnerships and collaborations,
integration with existing programs, creation of morbidity
management programs, the motivation of community
drug distributors (CDDs) through incentives and train-
ing, and management of adverse effects.23
Conclusion
Low knowledge and unawareness of the MDA health
promotion proved to be the most dominant factor in non-
compliance to the MDA program.
Recommendation
Based on the findings, it is suggested that the govern-
ment can improve health promotion programs by con-
ducting counseling activities or distributing brochures
and leaflets to the community to increase public knowl-
edge about the benefits of the MDA program for filariasis
and for the community to participate actively in the MDA
program. Besides, it is hoped that it will further enhance
the systematic post-MDA surveillance using TAS for epi-
demiological assessment of recent LF transmission and
monitoring/evaluation activities of the MDA program to
find out how the program's obstacles are faced along
with formulating solutions to the problems that occur.
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